FDA warns ‘Dr. Goodenowe’ health centre founder that his recent supplement study put patient health at risk – CBC
Journal where Goodenowe’s study was published posts a warning on the article and launches investigation
Feb 01, 2026
The U.S. Food and Drug Administration (FDA) has rebuked the founder of Moose Jaw, Sask.’s controversial Dr. Goodenowe Restorative Health Center, alleging that a recent clinical trial of his supplements put the safety and welfare of research subjects at risk.
On Jan. 20, the FDA publicly posted a warning letter to Dayan Goodenowe and his company Prodrome Sciences USA, LLC, which manufactures pills and oils that he has claimed can help stop and reverse the progression of conditions like ALS, Alzheimer’s and autism.
The FDA says that between 2020 and 2021, Goodenowe enrolled 29 people in a clinical trial evaluating whether his product, ProdromeNeuro, was safe and tolerable for patients with mild to moderate dementia.
